Cel-Sci Corporation (CVM)
|Net Income (ttm)||-34.05M|
|Day's Range||11.75 - 12.24|
|52-Week Range||7.08 - 40.91|
|Price Target||12.00 (+0.4%)|
|Est. Earnings Date||Dec 28, 2021|
CEL-SCI Corporation engages in the research and development of immunotherapy for the treatment of cancer and infectious diseases. The company's lead investigational immunotherapy is Multikine, which is under phase III clinical trial for the treatment of head and neck cancer. Its Ligand Epitope Antigen Presentation System (LEAPS), a pre-clinical patented T-cell modulation process that stimulates the human immune system to fight bacterial, viral, and parasitic infections, as well as autoimmune diseases, allergies, transplantation rejections, and ... [Read more...]
In 2020, CVM's revenue was $597,427, an increase of 11.51% compared to the previous year's $535,776. Losses were -$30.28 million, 36.8% more than in 2019.Financial Statements
VIENNA, Va.--(BUSINESS WIRE)---- $CVM #Multikine--CEL-SCI Corporation reports third quarter fiscal 2021 financial results.
The company attempted to clarify "confusion" related to its recent late-stage clinical results.
VIENNA, Va.--(BUSINESS WIRE)---- $CVM #HeadandNeckCancer--CEL-SCI Corporation issues letter to shareholders.
VIENNA, Va.--(BUSINESS WIRE)---- $CVM #HeadandNeckCancer--The discussion of the results of CEL-SCI's Phase 3 Trial is now available.
CEL-SCI Corporation (NASDAQ:CVM) shares are trading lower by 27% at $9.33 on continued downward momentum following data from a Phase 3 Study of Multkine showing a 14.1% 5-year survival benefit in groups...
CEL-SCI to Conduct Investor Call Regarding Phase 3 Results Following Annual Shareholder Meeting on July 1, 2021
VIENNA, Va.--(BUSINESS WIRE)---- $CVM #Multikine--CEL-SCI to Conduct Investor Call Regarding Phase 3 Results Following Annual Shareholder Meeting on July 1, 2021
Everything went the wrong way for Cel-Sci.
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of CEL-SCI Corporation - CVM
NEW YORK, June 29, 2021 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of CEL-SCI Corporation ("CEL-SCI" or the "Company") (NYSE: CVM). Such investors are advised to cont...
Today, the trial results reported by Cel-Sci missed the mark, and investors are pricing in additional risks with CVM stock. The post CVM Stock: The Big Trial News That Has Cel-Sci Plunging Today appeare...
CEL-SCI's Immunotherapy Achieves Survival Benefit Of 14% Exceeding Pre-Defined 10% In Head & Cancer Patients
CEL-SCI Corporation (NYSE: CVM) has announced results from its Phase 3 study for its immunotherapy Multikine for advanced previously untreated squamous cell carcinoma of the head and neck (SCCHN). In th...
CEL-SCI's Multikine® Immunotherapy Produces Significant 14.1% 5-Year Survival Benefit (62.7% Vs 48.6%) in the Group R...
VIENNA, Va.--(BUSINESS WIRE)---- $CVM #Multikine--Multikine immunotherapy produces significant 14.1% 5-Year survival benefit in group receiving surgery plus radiotherapy in landmark Phase 3 Study.
VIENNA, Va.--(BUSINESS WIRE)---- $CVM--CEL-SCI Corporation invites participants to pre-submit questions for Annual Shareholder Meeting.
VIENNA, Va.--(BUSINESS WIRE)---- $CVM--CEL-SCI announces the closing of $31.7 million bought deal offering.
CEL-SCI Corporation (NYSE: CVM) has increased the size of its previously announced capital raise offering to 1.4 million shares, up from 1 million shares, at $22.62 per share representing a 5% discount ...
VIENNA, Va.--(BUSINESS WIRE)---- $CVM--CEL-SCI Increases Previously Announced Bought Deal to $31.7 Million.
VIENNA, Va.--(BUSINESS WIRE)-- #CVM--CEL-SCI Announces Bought Deal Offering
Big news is coming for CEL-SCI, and we don't know which way the stock will move.
VIENNA, Va.--(BUSINESS WIRE)---- $CVM #Multikine--CEL-SCI Corporation reports second quarter fiscal 2021 financial results.
VIENNA, Va.--(BUSINESS WIRE)--CEL-SCI Corporation reports first quarter fiscal 2021 financial results.
Investors are betting that these three stocks could turn them into millionaires in incredibly short periods of time. Will they succeed?
CVM stock is on the move after Cel-Sci CEO Geert Kersten joined the battle against GME stock short-sellers. Here's what to know.
VIENNA, Va.--(BUSINESS WIRE)--CEL-SCI Corporation to Present at the 2021 H.C. Wainwright BIOCONNECT Virtual Conference
VIENNA, Va.--(BUSINESS WIRE)--CEL-SCI Corporation issues letter to shareholders.